Mood, drowsiness, depressive mood, Energy/Tiredness/Tension/Calmness, sleep parameters, resting heart rate, IFN-gamma, TNF-alpha, TGF-beta1, il-1 & il-6, dim light melatonin onset, cortisol (at bedtime), and metabolomics health well-being
Conditions
Interventions
5 conditions will be tested: 2 PBM doses: 0 J.cm-2 (placebo), and 6.5 J.cm-2.
The PBM dose will either have a wavelength of 850 or 940 nm and a pulse of
either 15 Hz/8 ms or 100 Hz/1.2 ms, respectiv
Sponsors
Seaborough Life Sciences B.V.
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: • Healthy, no chronic disease • Age between 25 - 65 years. • Suffer from daytime sleepiness/drowsiness and or a mild mood disturbance (ESS >5 or BDI equal to or higher than 13 but lower than 20) • Participants will have to have a desk type of work and/or have 3 hours per day between 9:30 am and 12:30 at their office/home in which they could sit in front of the lamp.
Exclusion criteria
Exclusion criteria: . Depressive mood (BDI -II > 20) • Pregnancy • Menopause symptoms • Drug use during the last three months known to interfere with sleep, alertness, the biological clock and/or light sensitivity (i.e. regular usage of sleep medication or stimulating substances) • Use of immune suppressants. High levels of caffeine intake during a day (5 or more cups, according to https://www.voedingscentrum.nl/encyclopedie/cafeine.aspx#blok7, there are no negative effects expected from 4 caffeine products in normal adults) • High alcohol intake (more than 4 for men and more than 3 for women, drinks per day) for more than 5 days in the past month, including binge drinking and heavy drinking according to https://www.niaaa.nih.gov/publications/brochures-and- fact-sheets/alcohol-facts-and-statistics. • Participant is not able to refrain from using recreational drugs during the 4 weeks of the study. • Shift work schedule in the 3 months prior to participation and/or planned during the 2 weeks of the study • Environmental factors in everyday life that may disturb sleep and cannot be prohibited (e.g. young children, noisy environment) • Travel over 2 or more time zones in the month prior to participation • Travel to sunny holiday locations/wintersports 1 month before participation • Personal plans that prevent them for using the intervention during 2 consecutive weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PBM effects on immune system and its dependency on wavelength and/or pulse, as well as the role of the eyes in facilitating PBM effects. | — |
Secondary
| Measure | Time frame |
|---|---|
| PBM effects on other aspects of health (resting heart rate) and well-being (and their dependency on wavelength and/or pulse, as well as the role of the eyes in facilitating PBM effects. We will also assess pathways of action by means of metabolomics analysis. | — |
Countries
Netherlands
Outcome results
None listed